BioInvent International AB Year-end Report January 1 - December 31, 2023 - Seite 2

Financial information
Fourth quarter 2023

• Net sales SEK 15.3 (20.6) million.
• Profit/loss after tax SEK -97.2 (-78.3) million.
• Profit/loss after tax per share before and after dilution SEK -1.48 (-1.21).
• Cash flow from operating activities SEK -72.4 (-71.7) million.

January - December 2023

• Net sales SEK 71.5 (326.1) million.
• Profit/loss after tax SEK -330.3 (-42.5) million.
• Profit/loss after tax per share before and after dilution SEK -5.02 (-0.69).
• Cash flow from operating activities SEK -341.7 (-41.2) million.
• Liquid funds, current and long-term investments as of December 31, 2023: SEK 1,283.0 (1,593.6) million.

Note to reader. Figures in parentheses refer to the outcome for the corresponding period in the preceding year.

Read the complete report in the attached pdf.

INVITATION TO PRESENTATION OF YEAR-END REPORT 2023
BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.
When: Thursday February 22, 2024, at 2:00 pm CET
Listen to the presentation webcast: https://financialhearings.com/event/48630
To participate via teleconference, please register via the following link: https://conference.financialhearings.com/teleconference/?id=50048630.
Upon registration, a phone number and conference ID for the conference call will be provided. You can ask questions verbally via the telephone conference.
The conference call will be made available on the company website after the call.

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.